HIMS / Hims & Hers Health, Inc. (HIMS) Q4 2022 Earnings Call Transcript

While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major r more_horizontal

Hims & Hers Health offers personalized and customized telehealth services, specializing in niche treatments for hair loss, erectile dysfunction, skinc more_horizontal

Hims & Hers is cutting prices, but profit margins are rising. The company is cash flow positive, with plenty of cash on the balance sheet. more_horizontal

Hims & Hers reported strong earnings and raised its full-year guidance, but its stock continues to decline. Hims & Hers is focusing on personalization more_horizontal

Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report qu more_horizontal

Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SP more_horizontal

Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%. more_horizontal

Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories more_horizontal